NVCT earnings: real EPS beat/miss history, analyst consensus Buy, P/E -14.73. Updated 2026-07-23.
Nuvectis Pharma (NVCT) Research Hub
Nuvectis Pharma (NVCT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 23.99 USD (+5.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.73, market cap 0.51B. This hub links to the full technical, earnings and options research available for NVCT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.99 USD (+5.31%) |
| 52-week range | 10.73 USD – 28.37 USD |
| Trend regime | Range |
| 14-day RSI | 67.1 (Bullish) |
| Trailing P/E | -14.73 |
| Market cap | 0.51B |
| Dividend yield | 0.00% |
Available research for NVCT
Covered Call on NVCT: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVCT: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVCT: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
NVCT technical analysis: range, last 23.99 USD, RSI 67.1, 52w range 10.73 USD–28.37 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NVCT in?
Nuvectis Pharma (NVCT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NVCT in an uptrend or downtrend?
As of 2026-09-11, NVCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVCT's trailing P/E ratio?
NVCT's trailing P/E is -14.73, with a market cap of 0.51B. See the earnings research page for full valuation detail.